重组人生长激素治疗青春后期特发性矮小临床观察

Effect of recombinant human growth hormone therapy on late puberty children with idiopathic short stature

目的探讨基因重组人生长激素(rhGH)对青春后期特发性矮小的促生长效应。方法 11例青春后期矮小患儿,按性别分为2组,A组,男5例,骨龄14～15岁,B组,女6例,骨龄12.5～13.5岁,每晚睡前皮下注射rhGH,剂量0.15 IU/(kg.d),疗程6个月。结果 2组患儿的身高分别由治疗前(148.6±2.6)cm、(139.6±2.9)cm增加到(153.6±2.1)cm、(143.8±2.5)cm,生长速率分别由治疗前(3.8±0.5)cm/年、(3.3±0.6)cm/年,提高到(9.8±1.7)cm/年、(8.4±1.8)cm/年,预测成年身高由治疗前(158.9±3.0)cm、(147.6±1.2)cm提高到(160.3±3.0)cm、(149.2±1.6)cm,与治疗前相比均有显著性差异(P<0.05),骨龄增加较治疗前相比无显著性差异(P>0.05)。结论 rhGH治疗对青春后期特发性矮小儿童有促生长效应,疗效肯定,无明显不良反应。

Objective To assess the efficacy of recombinant human growth hormone （rhGH） therapy in late puberty children with idiopathic short stature. Methods 11 children in late puberty with idiopathic short stature（ISS） were divided into 2 groups according to sex. A group consisted of 5 boys , B group was composed of 6 girls. Bone age（BA） of A group was （ld -15）years, and BA of B group was （12.5 -13.5 ） years. The enrolled children were treated with subcutaneous injection of rhGH （0.15 IU/kg · d） daily before sleep for six months, and the growth velocities （GV） and the predicted adult height （PAH） before and after treatment were compared. Results The mean height of A group and B group increased from （148.6 ±2.6） cm and （139.6±2.9） cm to （153.6 ±2.1 ） cm and （143.8 ±2.5） cm respectively. The growth velocity of A group and B group increased from （3.8± 0.5） cm and（3.3 ±0.6） cm per year to（9.8＋1.7） cmand （8.4＋1.8） cmperyear. PAH of A group and B group increased from （158.9± 3. O） cm and（ 147.6 ± 1.2） cm to（ 160.3 ± 3.0） cm and （ 149.2± 1.6） cm. There was a significant increase in rhGH therapy（ all P 〈 0.05） ,but no change in BA during the whole course of rhGH therapy. Conclusion rhGH was an effective and safe drug in promoting the growth in late puberty children with ISS.